Comparative Pharmacology
Head-to-head clinical analysis: DIANEAL PD 2 W DEXTROSE 3 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 3 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIANEAL PD 2 W DEXTROSE 3 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 3 5 IN PLASTIC CONTAINER.
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER vs INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dianeal PD-2 with Dextrose 3.5% is a peritoneal dialysis solution. Dextrose provides an osmotic gradient that facilitates the removal of uremic toxins and excess fluid from the blood across the peritoneal membrane into the dialysate. The solution also contains electrolytes to correct imbalances.
Inpersol-LC/LM with 3.5% dextrose is a peritoneal dialysis solution that provides osmotic ultrafiltration via dextrose, removing waste products and excess fluid from the blood across the peritoneal membrane. The low calcium (LC) and low magnesium (LM) formulations adjust electrolyte concentrations to manage imbalances.
2 to 3 liters intraperitoneally, 4 exchanges daily, with dwell times of 4-6 hours for CAPD; or 2 to 2.5 liters intraperitoneally, cycler-assisted, 3-5 cycles nightly for APD. Dextrose 3.5% solution used based on ultrafiltration needs.
Intraperitoneal administration: 2 to 2.5 liters per exchange, 4 to 5 exchanges per day, as prescribed by physician based on peritoneal equilibration test.
None Documented
None Documented
The elimination half-life of dextrose from the systemic circulation is approximately 3.5-4.5 hours after intraperitoneal administration. Clinically, this reflects the rate of glucose absorption and metabolism, which can be altered in patients with impaired glucose tolerance or diabetes.
Not applicable; dextrose is continuously infused and removed; the half-life of intraperitoneal dextrose is approximately 1-2 hours due to rapid absorption and metabolism, with clinically relevant hyperglycemia managed by insulin.
Peritoneal dialysis (PD) with 3.5% dextrose solution results in elimination of excess fluid and solutes via the peritoneal membrane. Dextrose is absorbed systemically and metabolized. The primary route of elimination of dialytic waste products (e.g., urea, creatinine) is via the peritoneal fluid itself, which is drained. Less than 1% of dextrose is excreted unchanged in urine. Biliary/fecal excretion is negligible.
Renal (via peritoneal dialysis effluent); approximately 60-70% of administered dextrose is absorbed and metabolized, with the remainder removed in dialysate; no significant biliary/fecal elimination.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution